<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Obesity on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/obesity/</link><description>Recent content in Obesity on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Wed, 10 Jun 2026 07:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/obesity/index.xml" rel="self" type="application/rss+xml"/><item><title>Dosing Biologic Drugs in Obesity: One Size Does Not Fit All</title><link>https://rheumatologydigest.org/posts/dosing-biologics-obesity/</link><pubDate>Wed, 10 Jun 2026 07:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/dosing-biologics-obesity/</guid><description>A 2026 clinical-pharmacology perspective arguing that biologic treatment failure in obesity is partly a pharmacokinetic problem: weight-driven clearance leaves many patients on fixed-dose subcutaneous biologics systematically underdosed, and dosing strategy should be matched to the weight–clearance relationship.</description></item></channel></rss>